在儿科急性淋巴细胞白血病中药物耐药性的图书统计分析
Alireza Khanahmad1,2, Mohammad Hossein Khazaee-Nasirabadi3, Mahshid Lotfi4
1Student Research Committee, Afzalipour Faculty of Medicine, Kerman University of Medical Sciences, Kerman, Iran.
Advanced biomedical research
|November 27, 2025
概括
儿科急性淋巴细胞白血病 (ALL) 的药物耐药性是一个重大挑战. 这种图书统计分析绘制了全球研究趋势,确定了关键的生物机制和治疗剂,以便在未来进行研究.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 儿科医学 儿科医学
背景情况:
- 耐药性仍然是治疗急性淋巴细胞白血病 (ALL) 的关键障碍,尽管治疗方面取得了进展.
- 儿科ALL在克服治疗耐药性方面存在独特的挑战.
- 了解全球研究趋势对于解决儿科ALL耐药性至关重要.
研究的目的:
- 提供关于儿科ALL药物耐药性的全球研究的综合图书统计概述.
- 确定新兴的研究方向和该领域的关键贡献者.
- 突出与儿科ALL药物耐药性相关的重要生物机制和治疗剂.
主要方法:
- 来自科学网络核心集合的论文的图书统计分析.
- 使用了诸如"急性淋巴细胞白血病"",儿科"和"耐药性"等关键词.
- 数据可视化和分析使用Biblioshiny和VOSviewer进行.
主要成果:
- 分析了来自48个国家的432篇原始和94篇评论文章.
- 美国在出版物 (148篇文章) 和引用 (9569) 方面领先.
- 关键的研究主题包括改变的葡萄糖皮质激素反应,P-gp过度表达,microRNA作用,和特定的药物,如克洛法拉宾和尼拉拉宾.
结论:
- 关于儿科ALL耐药性的研究是多方面的,吸引了全球的重大关注.
- 这种文献计量分析绘制了当前的研究格局,并确定了未来研究的关键领域.
- 需要对克洛法拉宾,内拉拉宾,鲁比辛,温克里斯和microRNA等药物的临床应用和耐药性机制进行进一步的研究.
相关概念视频
02:56Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
195
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
195
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
244
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
244
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
176
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
176
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
231
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
231